NuPathe Inc (fka PATH) (PATH)

[surf1944]

NuPathe, Inc. (PATH) has a PDUFA date of August 29 for Zelrix, its transdermal patch for the treatment of migraines. The active ingredient in Zelrix is sumatriptan, the most commonly prescribed drug for migraine treatment. The sumatriptan is administered via NuPathe’s proprietary SmartRelief technology, a controlled delivery technology that uses a mild electrical current to actively deliver medication through the skin in a process called iontophoresis. Not only would an approval provide NuPathe with the obvious financials of a marketed drug, but it would also legitimize its SmartRelief technology, which would likely be utilized to deliver other drugs for the company or for potential licensees. More information on Zelrix may be viewed at the company’s website.

http://seekingalpha.com/article/276594-biotech-catalysts-for-third-quarter?source=yahoo